Frontiers in Aging Neuroscience最新文献

{"title":"Improving cognitive impairment through chronic consumption of natural compounds/extracts: a systematic review and meta-analysis of randomized controlled trials.","authors":"Long Ngo Hoang, Haesung Lee, Sook Jeong Lee","doi":"10.3389/fnagi.2024.1531278","DOIUrl":"10.3389/fnagi.2024.1531278","url":null,"abstract":"<p><strong>Introduction: </strong>This systematic review and meta-analysis aimed to compare the efficacy of extended supplementation (≥6 weeks) with natural compounds or extracts in improving cognitive function in patients with mild cognitive impairment (MCI) or Alzheimer's disease (AD).</p><p><strong>Methods: </strong>A comprehensive literature search was conducted across Cochrane, PubMed, PsycARTICLES, Scopus, and Web of Science databases from inception to April 10, 2024. Eligible studies were randomized controlled trials evaluating cognitive outcomes in patients with MCI or AD using the Mini-Mental State Examination (MMSE) and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog).</p><p><strong>Results: </strong>From an initial pool of 6,687 articles, 45 were deemed relevant for qualitative analysis. Of these, 37 studies demonstrated improvements or positive trends in cognitive outcomes with natural compound or extract supplementation. A total of 35 studies met the criteria for meta-analysis. The meta-analysis, involving 4,974 participants, revealed significant improvements in ADAS-Cog scores (pooled standardized mean difference = -2.88, 95% confidence interval [CI]: -4.26 to -1.50; t₂₄ = -4.31, <i>p</i> < 0.01) following supplementation. Additionally, a suggestive trend toward improvement in MMSE scores was observed in a subgroup analysis of 1,717 participants (pooled standardized mean difference = 0.76, 95% CI: 0.06 to 1.46, t₁₈ = 2.27, <i>p =</i> 0.04).</p><p><strong>Conclusion: </strong>These findings support the potential cognitive benefits of extended (≥6 weeks) supplementation with natural compounds or extracts in individuals with MCI or AD. Further research is warranted to confirm these results and elucidate the underlying mechanisms.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"16 ","pages":"1531278"},"PeriodicalIF":4.1,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11821934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebellar-cerebral circuits functional connectivity in patients with cognitive impairment after basal ganglia stroke: a pilot study.","authors":"Lijun Zuo, Xinlong Lan, Yijun Zhou, Hao Liu, Yang Hu, Yongjun Wang, Tao Liu, Zixiao Li","doi":"10.3389/fnagi.2025.1478891","DOIUrl":"10.3389/fnagi.2025.1478891","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to assess the pattern of functional connectivity (FC) between cerebellar subregions, the basal ganglia (BG), and the cortex, and explore the relationship between FC patterns and cognitive function after stroke with BG infarcts.</p><p><strong>Methods: </strong>A total of 39 stroke patients and 29 healthy controls were recruited. Four cerebellar seed points were selected, and the FC of each seed point with other voxels in the whole brain was calculated. FC and cognitive performance were compared between the two groups, and their correlations were analyzed.</p><p><strong>Results: </strong>Stroke patients exhibited increased FC between the bilateral cerebellum IX and BG (particularly the head of the caudate nucleus), which was positively correlated with episodic memory, visuospatial ability, and attention. Increased FC was also observed between the right cerebellum Crus I/II and BG, as well as the bilateral cerebellum VI and BG, correlating positively with episodic memory. Conversely, decreased FC was identified between the bilateral cerebellum IX and the right caudal cuneus, which negatively correlated with episodic memory, language, and attention but positively correlated with executive function. Additionally, increased FC between the bilateral cerebellum VI and the bilateral inferior parietal lobule was associated with improvements in episodic memory, language, and attention. Decreased FC was observed between the right cerebellum VI and the left insula, as well as between the right cerebellum Crus I/II and the left insula, which negatively correlated with episodic memory.</p><p><strong>Discussion: </strong>The enhanced FC between the cerebellum and BG, along with the reorganization of new neural circuits involving the cerebellar cortex, may contribute to cognitive recovery following stroke. These changes may represent compensatory mechanisms of the cerebellum in response to stroke injury.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1478891"},"PeriodicalIF":4.1,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11821925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and internal validation of a nomogram for predicting cognitive impairment after mild ischemic stroke and transient ischemic attack based on cognitive trajectories: a prospective cohort study.","authors":"Panpan Zhao, Lin Shi, Guimei Zhang, Chunxiao Wei, Weijie Zhai, Yanxin Shen, Yongchun Wang, Zicheng Wang, Li Sun","doi":"10.3389/fnagi.2025.1427737","DOIUrl":"10.3389/fnagi.2025.1427737","url":null,"abstract":"<p><strong>Introduction: </strong>Many predictive models for cognitive impairment after mild stroke and transient ischemic attack are based on cognitive scales at a certain timepoint. We aimed to develop two easy-to-use predictive models based on longitudinal cognitive trajectories to facilitate early identification and treatment.</p><p><strong>Methods: </strong>This was a prospective cohort study of 556 patients, followed up every 3 months. Patients with at least two cognitive scales within 2.5 years were included in the latent class growth analysis (LCGA). The patients were categorized into two groups based on the LCGA. First, a difference analysis was performed, and further univariate and stepwise backward multifactorial logistic regression was performed. The results were presented as nomograms, and receiver operating characteristic curve analysis, calibration, decision curve analysis, and cross-validation were performed to assess model performance.</p><p><strong>Results: </strong>The LCGA eventually included 255 patients, and the \"22\" group was selected for further subgroup analysis. Among them, 29.8% were included in the cognitive impairment trajectory. Model 1, which incorporated baseline Montreal Cognitive Assessment, ferritin, age, and previous stroke, achieved an area under the curve (AUC) of 0.973, and model 2, which incorporated age, previous stroke, education, and ferritin, with an AUC of 0.771. Decision curve analysis and cross-validation showed excellent clinical applicability.</p><p><strong>Discussion: </strong>Here, we developed two simple and easy-to-use predictive models of post-stroke cognitive trajectories based on a LCGA, which are presented in the form of nomograms suitable for clinical application. These models provide a basis for early detection and prompt treatment.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1427737"},"PeriodicalIF":4.1,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11814159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trials.","authors":"Wenting Cai, Hui Zhang, Yan Wu, Yao Yao, Jinping Zhang","doi":"10.3389/fnagi.2024.1465871","DOIUrl":"10.3389/fnagi.2024.1465871","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to compare the efficacy and safety of anti-tau protein monoclonal antibodies for Alzheimer's disease (AD). Tau protein aggregation, a key pathological feature of AD, is closely associated with neurodegeneration and cognitive decline. Targeting tau protein has emerged as a promising therapeutic strategy. By investigating the effects of monoclonal antibodies on cognitive function, disease progression, and overall quality of life in patients with AD, which can provide valuable insights into their potential as a therapeutic option for this devastating neurodegenerative disorder.</p><p><strong>Methods: </strong>The randomized controlled trials (RCTs) investigating the efficacy of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in Alzheimer's disease (AD) were systematically searched across PubMed, Embase, Web of Science and Cochrane Library, up to May 2024. The control group included placebo. The efficacy indicators were change in the Mini Mental State Examination (MMSE), Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog), Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL) from baseline until the time of efficacy observation. Statistical analysis was conducted using Stata 14 and RevMan 5.4. The purpose of data processing, including generating network evidence plots, surface under the cumulative ranking curve (SUCRA) ranking, league plots, and funnel plots, is to visually summarize and evaluate the relative effectiveness and safety and potential publication bias of multiple interventions. Mean differences (MD) and 95% confidence interval (95%CI) as effect sizes to analyze continuous variables.</p><p><strong>Results: </strong>This study encompassed six RCTs involving 2,193 patients. Semorinemab were more effective than placebo in MMSE and ADAS-Cog scores (MDs ranging between 0.52 and 3.21; MDs ranging between 0.17 and 3.30). Placebo showed relatively good efficacy according to SUCRA ranking on change in CDR-SB and ADCS-ADL scores (75.7 and 79.5%). Tilavonemab and Semorinemab exhibited efficacy similar to that of a placebo in the analysis of the two indicators. Tilavonemab showed a lower incidence of AE, SAE, fall, and urinary tract infections than placebo, and the differences were statistically significant. Most safety analysis results showed no statistical difference.</p><p><strong>Conclusion: </strong>The results indicated that anti-tau protein monoclonal antibodies, such as Semorinemab and Tilavonemab, showed promise in terms of efficacy and safety for managing AD. Further studies are needed to confirm these findings, assess long-term effects, and refine treatment protocols.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/#myprospero, CRD42024583388.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"16 ","pages":"1465871"},"PeriodicalIF":4.1,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11814219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From hypoxic pockets to daily routines: linking brain oxygenation and cognitive resilience.","authors":"Dian Jiao","doi":"10.3389/fnagi.2025.1534198","DOIUrl":"10.3389/fnagi.2025.1534198","url":null,"abstract":"<p><p>The discovery of hypoxic pockets within the cortical regions has transformed the understanding of cerebral oxygen dynamics, revealing their dual role as both contributors to neuronal adaptation and potential precursors to dysfunction. These transient oxygen-deprived microenvironments play a pivotal role in neurovascular coupling, synaptic plasticity, and angiogenesis, processes crucial for maintaining cognitive resilience and neuronal health. Investigating hypoxic pockets within cortical regions is particularly relevant in aging populations and individuals with neurodegenerative conditions. Concurrently, research underscores the ability of physical, social, and cognitive activities to modulate brain oxygenation, offering natural, accessible interventions to optimize oxygen delivery and utilization. This study synthesizes findings from neuroimaging, behavioral science, and longitudinal studies, illustrating how daily routines can mitigate hypoxia-induced cognitive decline and promote resilience. By integrating insights from centenarians, hypoxia-adapted species, and multimodal intervention studies, this framework highlights the transformative potential of lifestyle-based strategies in addressing cerebral oxygen deficits. The findings advocate for an interdisciplinary approach to develop targeted interventions for public health, rehabilitation, and personalized cognitive care.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1534198"},"PeriodicalIF":4.1,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11814472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-functional role of apolipoprotein E in neurodegenerative diseases.","authors":"Sadequl Islam, Arshad Noorani, Yang Sun, Makoto Michikawa, Kun Zou","doi":"10.3389/fnagi.2025.1535280","DOIUrl":"10.3389/fnagi.2025.1535280","url":null,"abstract":"<p><p>Genetic diversity in the apolipoprotein E (ApoE) gene has been identified as the major susceptibility genetic risk factor for sporadic Alzheimer's disease (SAD). Specifically, the <i>ApoEε4</i> allele is a significant risk factor for SAD, while <i>ApoEε2</i> allele provides protection compared to the more common <i>ApoEε3</i> allele. This review discusses the role of the ApoE in AD and other neurodegenerative disorders. ApoE, a cholesterol transport protein, influences several pathways involved in neurodegeneration, particularly in AD. Beyond its established role in amyloid <i>β</i>-protein (Aβ) metabolism and deposition, ApoE also impacts tau pathology, neurodegeneration, and the microglial response to AD. The review aims to provide an updated overview of ApoE's diverse roles, emphasizing its involvement in Aβ clearance through ApoE receptors. It also covers ApoE's influence in other neurodegenerative diseases like Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal lobar degeneration (FTLD), Huntington's disease (HD), vascular dementia (VD), and multiple sclerosis (MS). New research highlights the interaction between ApoE and presenilin (PS), suggesting connections between familial AD (FAD) and SAD. The review also explores protective effects of ApoE mutations against AD and ApoE4-induced tauopathy, neurodegeneration, and neuroinflammation. The insights from this comprehensive update could indeed lead to new therapeutic strategies for neurodegenerative diseases.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1535280"},"PeriodicalIF":4.1,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertension moderates the relationship between plasma beta-amyloid and cognitive impairment: a cross-sectional study in Xi'an, China.","authors":"Ziyu Liu, Yaoli He, Simeng Cui, Liangjun Dang, Binyan Zhang, Jin Wang, Wenhui Lu, Kang Huo, Yu Jiang, Chen Chen, Ling Gao, Shan Wei, Yi Zhao, Ningwei Hu, Jingyi Wang, Hong Lv, Qiumin Qu, Suhang Shang","doi":"10.3389/fnagi.2025.1532676","DOIUrl":"10.3389/fnagi.2025.1532676","url":null,"abstract":"<p><strong>Background: </strong>Plasma beta-amyloid (Aβ) are important biomarkers for Alzheimer's disease and cognitive impairment (CI), but results are controversial. It remains unclear whether hypertension modulates their relationship. This cross-sectional study investigates whether hypertension moderates the relationship between plasma Aβ and cognitive impairment (CI).</p><p><strong>Methods: </strong>This cross-sectional study included 1488 subjects ≥ 40 years from rural areas of northwestern China. CI was defined as a Mini-Mental State Examination score lower than the cutoff. Firstly, plasma Aβ₄₀, Aβ₄₂, Aβ₄₂/Aβ₄₀ were analyzed as restricted cubic spline. Then, categories of combined plasma Aβ were created by making bisection of plasma Aβ according to average and combining them as L-Aβ₄₀ and L-Aβ₄₂, H-Aβ₄₀ and L-Aβ₄₂, L-Aβ₄₀ and H-Aβ₄₂, H-Aβ₄₀ and H-Aβ₄₂. Decreased plasma Aβ₄₀ was defined as < 25th percentile. Multivariate logistic regression examined the relationship between plasma Aβ and CI in total population, the hypertension subgroup and the non-hypertension subgroup.</p><p><strong>Results: </strong>737 participants (49.5%) had hypertension and 189 participants (12.7%) had CI. Simultaneously elevated plasma Aβ₄₀ and Aβ₄₂ was associated with CI in hypertension (H-Aβ₄₀ and H-Aβ₄₂ vs. L-Aβ₄₀ and L-Aβ₄₂, 21.1% vs.10.7%, <i>P</i> = 0.033; OR = 1.984 [95% CI, 1.067-3.691], <i>P</i> = 0.030) but not in the non-hypertension. Decreased plasma Aβ₄₀ was associated with CI in the non-hypertension (14.9% vs. 9.2%, <i>P</i> = 0.026; OR = 1.728 [95% CI, 1.018-2.931], <i>P</i> = 0.043) but not in the hypertension.</p><p><strong>Conclusion: </strong>Hypertension is an important modulator in the relationship between plasma Aβ and CI. Simultaneously elevated plasma Aβ₄₀ and Aβ₄₂ in the hypertension, and decreased plasma Aβ₄₀ in the non-hypertension, may be risk factors for CI. These findings emphasize the need to consider hypertension in CI detection.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1532676"},"PeriodicalIF":4.1,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11810958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Untargeted urine metabolomics reveals dynamic metabolic differences and key biomarkers across different stages of Alzheimer's disease.","authors":"Xiaoya Feng, Shenglan Zhao","doi":"10.3389/fnagi.2025.1530046","DOIUrl":"10.3389/fnagi.2025.1530046","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) is a progressive neurodegenerative disorder, with mild cognitive impairment (MCI) often serving as its precursor stage. Early intervention at the MCI stage can significantly delay AD onset.</p><p><strong>Methods: </strong>This study employed untargeted urine metabolomics, with data obtained from the MetaboLights database (MTBLS8662), combined with orthogonal partial least squares-discriminant analysis (OPLS-DA) to examine metabolic differences across different stages of AD progression. A decision tree approach was used to identify key metabolites within significantly enriched pathways. These key metabolites were then utilized to construct and validate an AD progression prediction model.</p><p><strong>Results: </strong>The OPLS-DA model effectively distinguished the metabolic characteristics at different stages. Pathway enrichment analysis revealed that Drug metabolism was significantly enriched across all stages, while Retinol metabolism was particularly prominent during the transition stages. Key metabolites such as Theophylline, Vanillylmandelic Acid (VMA), and Adenosine showed significant differencesdifferencesin the early stages of the disease, whereas 1,7-Dimethyluric Acid, Cystathionine, and Indole exhibited strong predictive value during the MCI to AD transition. These metabolites play a crucial role in monitoring AD progression. Predictive models based on these metabolites demonstrated excellent classification and prediction capabilities.</p><p><strong>Conclusion: </strong>This study systematically analyzed the dynamic metabolic differences during the progression of AD and identified key metabolites and pathways as potential biomarkers for early prediction and intervention. Utilizing urinary metabolomics, the findings provide a theoretical basis for monitoring AD progression and contribute to improving prevention and intervention strategies, thereby potentially delaying disease progression.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1530046"},"PeriodicalIF":4.1,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping hippocampal glutamate in healthy aging with <i>in vivo</i> glutamate-weighted CEST (GluCEST) imaging.","authors":"Maggie K Pecsok, Heather Robinson, Ally Atkins, Monica E Calkins, Mark A Elliott, Arianna Mordy, Jacquelyn Stifelman, Ruben C Gur, Paul J Moberg, Ravi Prakash Reddy Nanga, Kosha Ruparel, Russell T Shinohara, David A Wolk, Ravinder Reddy, David R Roalf","doi":"10.3389/fnagi.2024.1535158","DOIUrl":"10.3389/fnagi.2024.1535158","url":null,"abstract":"<p><strong>Introduction: </strong>Hippocampal glutamate (Glu) dysfunction is a pertinent indicator of neurodegeneration, yet mapping typical age-related changes in Glu has been challenging. Here, we use a 7T MRI approach, Glutamate Chemical Exchange Saturation Transfer (GluCEST), to measure bilateral hippocampal Glu in healthy old (HOA) and young (HYA) adults.</p><p><strong>Methods: </strong>Bilateral hippocampal GluCEST data was acquired from 27 HOA and 22 HYA using 7T MRI. GluCEST differences by age and hemisphere were tested with a linear mixed model. GluCEST asymmetry index was also evaluated by age. Exploratory analyses examined associations between hippocampal GluCEST, age group, and scores on the Montreal Cognitive Assessment (MoCA) and Cognitive Complaints Index (CCI).</p><p><strong>Results: </strong>GluCEST levels showed an age group and hemisphere interaction. In HOA, GluCEST was higher in left than right hippocampus, but in HYA, GluCEST level was equivalent across hemispheres. HOA had lower GluCEST than HYA in the right hippocampus. GluCEST asymmetry index confirmed significant left asymmetry in HOA. Lower GluCEST levels in HOA were associated with subjective cognitive complaints as measured by the CCI.</p><p><strong>Discussion: </strong>Hippocampal GluCEST provides insight into age-related neural changes, with lower GluCEST in the right hippocampus in older adults. These findings offer a step toward elucidating the asymmetrical trajectory of hippocampal glutamatergic alterations and their relationship to cognitive phenotypes.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"16 ","pages":"1535158"},"PeriodicalIF":4.1,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline liver fibrosis-4 score correlates to the progression of anxiety and cognitive impairment in patients with Parkinson's disease.","authors":"Yongqing Cheng, Li Chen, Honghong Zhu, Yingchao Ge, Lei Li, Yan Guo, Xin Wang, Shuangfei You, Guojun He, Shouru Xue","doi":"10.3389/fnagi.2025.1501319","DOIUrl":"10.3389/fnagi.2025.1501319","url":null,"abstract":"<p><strong>Background: </strong>Non-alcoholic fatty liver disease (NAFLD) or liver fibrosis may share similar pathophysiological features with Parkinson's disease (PD), yet their correlation was unclear. This study aimed to explore their correlation between PD and liver fibrosis using the fibrosis-4 score (FIB-4) as a surrogate marker.</p><p><strong>Methods: </strong>We analyzed Parkinson's Progression Markers Initiative (PPMI) data and enrolled PD patients with comprehensive baseline and 5-year follow-up time-point clinical data. Participants were categorized based on FIB-4 levels to assess the association between FIB-4 scores and various clinical scales, controlling for potential confounders. Differences in the progression of clinical scales over five years were compared using generalized linear mixed models (GLMM).</p><p><strong>Results: </strong>Baseline FIB-4 levels positively correlated to scores of baseline section III of the Unified-Parkinson Disease Rating Scale (UPDRS III) (<i>r</i> = 0.145, <i>p</i> = 0.017), Epworth Sleepiness Scale (EPSS) (<i>r</i> = 0.140, <i>P</i> = 0.022), Hopkins Verbal Learning Test (HVLT)-delayed recall (<i>r</i> = 0.128, <i>P</i> = 0.036) and HVLT-retention (<i>r</i> = 0.128, <i>p</i> = 0.036). GLMM analysis revealed an independent correlation between FIB-4 subgroup*time and several clinical scales including the State-trait Anxiety Inventory (STAI), Symbol Digit Modalities Test (SDMT), Semantic Fluency Test (SF), HVLT-total recall, and HVLT-delayed recall, with the high FIB-4 subgroup exhibiting a greater decline in these scores compared to the low FIB-4 subgroup (all <i>p</i><0.05).</p><p><strong>Conclusion: </strong>Elevated baseline FIB-4 correlated to more severe baseline daytime sleepiness, motor symptoms, and memory function in PD patients, along with a more rapid decline in cognitive functions such as executive function, information processing ability, and memory. Additionally, a high FIB-4 might confer a protective effect against anxiety.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1501319"},"PeriodicalIF":4.1,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11802528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}